Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
1 Year : From Jan 2019 to Jan 2020
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will host one-on-one meetings with investors at the 5th Annual SunTrust Robinson Humphrey (STRH) Annual Life Sciences Summit being held May 7-9, 2019 in New York, New York.
Investors attending the conference who are interested in meeting with Company management should contact their STRH representatives.
About EntasisEntasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ targeted-design platform has produced a pipeline of product candidates, including ETX2514SUL (targeting A. baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). For more information, visit www.entasistx.com.
Entasis Company Contact Kyle Dow Entasis Therapeutics (781) 810-0114 firstname.lastname@example.org
Investor Relations ContactTram BuiThe Ruth Group(646) email@example.com
Media ContactKirsten ThomasThe Ruth Group(508) firstname.lastname@example.org